Michael Jordan, MD, Differentiates Emapalumab Treatment in Pediatric Patients Versus Adults with HLH
The pediatrician discusses key differences between treating pediatric and adult patients with hemophagocytic lymphohistiocytosis (HLH) with the recently FDA-approved emapalumab.
CLL Therapy, Venetoclax/Rituximab, Shows Reduced Risk of Disease Progression
Full results from the phase 3 MURANO trial showed a reduced risk in disease progression and 87.9% overall survival in relapsed/refractory chronic lymphocytic leukemia patients treated with venetoclax/rituximab.
Anemia Patients with MDS Benefit from Luspatercept in Transfusion Burden
December 3rd 2018Currently available anemia therapies only provide benefit for about half of patients with a lower-risk myelodysplastic syndromes (MDS)-related condition—and about one-quarter of such patients dependent on red blood cell transfusions.
Q&A with Barbara Cappelli: HLA- Sibling Transplants Works in Sickle Cell Disease
Barbara Cappelli, MD, Eurocord International Registry, Paris, France, shared an overview from her team's study that found further evidence that for patients with severe sickle cell disease who have an HLA-identical sibling available as a donor, HSCT can be safe and effective.
Safety and Efficacy Profile of rFIXFc Treatment for Hemophilia
December 7th 2015The phase three studies, B-LONG and Kids B-LONG, examined outcomes with a hemophilia B therapy in adults and adolescents. Now an extension study went further to verify the findings and the results were presented at the 57th American Society of Hematology Annual Meeting (ASH 2015) in Orlando, Florida.
Parameters for Predicting Bleeding Events in Patients with Liver Disease
December 6th 2015Although the increased bleeding risk in patients with both acute and chronic liver disease is recognized, strategies to predict the occurrence are lacking. A team from South Korea discussed parameters to do just that during a poster session 57th American Society of Hematology Annual Meeting (ASH 2015) in Orlando, Florida.
Q&A with Christine Cserti-Gazdewich: The Progression in Blood Storage Duration
At the 57th American Society of Hematology Annual Meeting, Christine Cserti-Gazdewich, BSc, MD, Blood Transfusion Laboratory, Toronto General Hospital discussed the progress made in blood unit storage.
Q&A with Christine Cserti-Gazdewich: Blood Storage Duration, How Long Is Too Long?
Christine Cserti-Gazdewich, BSc, MD, Blood Transfusion Laboratory, Toronto General Hospital, and colleagues wanted to address the burgeoning concern that the longer blood units are stored, the likelier it may be to introduce harm or simply not work as well.
Q&A with Seth Karol, MD: Treating Pediatric Osteonecrosis
Seth Karol, MD, St. Jude's Children's Research Center and his team focused their research on the 10-20 age group, the "sweet spot" where the bones are still finishing up development and thus going to be susceptible to therapy.
Q&A with Seth Karol, MD: Risk Factors for Bone Toxicity for Patients with ALL
Seth Karol, MD, St. Jude's Children's Research Center discussed several ways in which he and his colleagues intensified therapy over the years and referred to a key toxicity that had emerged from the two drugs they used.